Showing 4371-4380 of 4942 results for "".
- New from Olay: Regenerist Micro-Sculpting Cream with SPF 30https://practicaldermatology.com/news/new-from-olay-regenerist-micro-sculpting-cream-with-spf-30/2458657/Olay introduced the newest member of the Regenerist family -- Regenerist Micro-Sculpting Cream with SPF 30 -- at the annual meeting of the American Academy of Dermatology in Washington, DC. Several studies presented here helped lay the groundw
- Cipher Pharmaceuticals Appoints New President and General Manager of US Businesshttps://practicaldermatology.com/news/cipher-pharmaceuticals-appoints-new-president-and-general-manager-of-us-business/2458662/Cipher Pharmaceuticals Inc. named Ralph Bohrer as President and General Manager of its US subsidiary. Mr. Bohrer is a seasoned pharmaceutical executive with 30 years of experience in sales and marketing leadership for growing dermatology companies. Prior to
- Syneron Candela Introducing New Technologies at the 2016 AAD Annual Meetinghttps://practicaldermatology.com/news/syneron-candela-introducing-new-technologies-at-the-2016-aad-annual-meeting/2458664/Syneron Medical Ltd., is launching three new products during the 2016 American Academy of Dermatology (AAD) meeting in Washington, DC. The launches include the new CO2RE Intima sy
- Khloé Kardashian Kicks Off Kybella Campaign in NYChttps://practicaldermatology.com/news/khlo-kardashian-kicks-off-kybella-campaign-in-nyc/2458669/Khloé Kardashian helped Allergan plc kick off their new Live Chin Up campaign. The campaign is designed to help encourage people to not let the things that bother them get in their way. At the event, Kardashian moderated a panel of experts who discussed submental fullnes
- Galderma to Begin Two Phase III Restylane Trialshttps://practicaldermatology.com/news/galderma-to-begins-two-phase-iii-restylane-trials/2458679/Galderma is set to initiate a pivotal Phase III trial on Restylane® Lyft for hand augmentation and another that will look to the safety of Restylane® Silk when ad
- Botox Helps Fuel Allergan's “Better-Than-Expected” Q4 Earningshttps://practicaldermatology.com/news/botox-helps-fuel-allergans-better-than-expected-q4-earnings/2458687/Allergan is reporting “better-than-expected” fourth-quarter earnings, largely fueled by Botox. The company saw a 74 percent increase in Q4 net revenue to $4.2 Billion for Q4 2015, topping the nearly $4.18 billion consensus estimate of S&a
- New Initiative Seeks To Raise Biosimilar Awareness, Accesshttps://practicaldermatology.com/news/new-initiative-to-raise-biosimilar-awareness-access/2458689/The Biosimilars Forum is launching a new biosimilars education initiative. The Partnership for Biosimilars Education and Access will focus on raising awareness and encouraging access to biosimilars in the United States. The Forum
- Cipher's Sitavig Accepted for Review by Health Canadahttps://practicaldermatology.com/news/ciphers-sitavig-accepted-for-review-by-health-canada/2458701/Cipher Pharmaceuticals Inc.’s New Drug Submission for Sitavig has been accepted for review by Health Canada. Sitavig (acyclovir mucoadhesive buccal tablets) is proposed for the treatment of recurrent herpes labialis in adults. In the United States, Sitavig® is approve
- FDA Accepts Allergan's sNDA for TEFLARO Use in Childrenhttps://practicaldermatology.com/news/fda-accepts-allergans-snda-for-teflaro-use-in-children/2458700/The U.S. Food and Drug Administration (FDA) has accepted Allergan’s supplemental New Drug Application (sNDA) for IV antibacterial TEFLARO® (ceftaroline fosamil). If approved, this filing will expand the label of TEFLARO beyond adults to include children two months of age a
- Phase 3 Data for BF-200 ALA Presented at the 14th South Beach Symposiumhttps://practicaldermatology.com/news/phase-3-data-for-bf-200-ala-presented-at-the-14th-south-beach-symposium/2458702/Biofrontera AG’s BF-200 ALA plus red light photodynamic therapy (PDT) shows good efficacy for the treatment of actinic keratoses (AK), according to data presented from three pivotal Phase III trials at the 14th Annual South Beach Symposium. The results were presented in a poster (Poster #11